Latest Cynata Therapeutics News

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

Cynata Therapeutics has successfully raised $1.2 million through an At-The-Market equity raise, issuing shares at a discount to support its ongoing clinical programs. This capital injection aims to bolster working capital as the company advances its proprietary stem cell therapies.

Cynata Therapeutics has finalised patient enrolment in its pivotal Phase 2 trial of CYP-001 for acute graft versus host disease, setting the stage for critical data due mid-2026.

Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.

Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.